KR20110128582A - 쉬와넬라 변이균주, 제조방법 및 그 용도 - Google Patents
쉬와넬라 변이균주, 제조방법 및 그 용도 Download PDFInfo
- Publication number
- KR20110128582A KR20110128582A KR1020100048104A KR20100048104A KR20110128582A KR 20110128582 A KR20110128582 A KR 20110128582A KR 1020100048104 A KR1020100048104 A KR 1020100048104A KR 20100048104 A KR20100048104 A KR 20100048104A KR 20110128582 A KR20110128582 A KR 20110128582A
- Authority
- KR
- South Korea
- Prior art keywords
- shiwanella
- hexasaccharide
- strain
- glucose
- gene encoding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title description 2
- 230000004060 metabolic process Effects 0.000 claims abstract description 31
- 239000000446 fuel Substances 0.000 claims abstract description 23
- 230000000813 microbial effect Effects 0.000 claims abstract description 22
- 108090000623 proteins and genes Proteins 0.000 claims description 84
- 102000004190 Enzymes Human genes 0.000 claims description 52
- 108090000790 Enzymes Proteins 0.000 claims description 52
- 239000013612 plasmid Substances 0.000 claims description 52
- 238000000034 method Methods 0.000 claims description 43
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 38
- 239000008103 glucose Substances 0.000 claims description 38
- 101150042675 glk gene Proteins 0.000 claims description 20
- 101150087955 glf gene Proteins 0.000 claims description 19
- 238000010521 absorption reaction Methods 0.000 claims description 18
- 241000588724 Escherichia coli Species 0.000 claims description 16
- 150000002402 hexoses Chemical class 0.000 claims description 14
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 13
- 235000000346 sugar Nutrition 0.000 claims description 13
- 108010078791 Carrier Proteins Proteins 0.000 claims description 12
- 229910021645 metal ion Inorganic materials 0.000 claims description 12
- 229930091371 Fructose Natural products 0.000 claims description 11
- 239000005715 Fructose Substances 0.000 claims description 11
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 11
- 229930182830 galactose Natural products 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 241000863430 Shewanella Species 0.000 claims description 8
- 230000001131 transforming effect Effects 0.000 claims description 8
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 7
- 229930195725 Mannitol Natural products 0.000 claims description 7
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims description 7
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims description 7
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims description 7
- 229930006000 Sucrose Natural products 0.000 claims description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 7
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 7
- 239000001913 cellulose Substances 0.000 claims description 7
- 229920002678 cellulose Polymers 0.000 claims description 7
- 239000000594 mannitol Substances 0.000 claims description 7
- 235000010355 mannitol Nutrition 0.000 claims description 7
- 229950006780 n-acetylglucosamine Drugs 0.000 claims description 7
- 239000005720 sucrose Substances 0.000 claims description 7
- 241001538194 Shewanella oneidensis MR-1 Species 0.000 claims description 6
- 101100448461 Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4) glf gene Proteins 0.000 claims description 6
- 101100336829 Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4) glk gene Proteins 0.000 claims description 6
- XDIYNQZUNSSENW-NUVHGKSTSA-N (2r,3s,4s,5r)-2,3,4,5,6-pentahydroxyhexanal;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O XDIYNQZUNSSENW-NUVHGKSTSA-N 0.000 claims description 5
- 101100190555 Dictyostelium discoideum pkgB gene Proteins 0.000 claims description 5
- 101100453320 Pyrococcus furiosus (strain ATCC 43587 / DSM 3638 / JCM 8422 / Vc1) pfkC gene Proteins 0.000 claims description 5
- 101100029403 Synechocystis sp. (strain PCC 6803 / Kazusa) pfkA2 gene Proteins 0.000 claims description 5
- 101150031187 fba gene Proteins 0.000 claims description 5
- 101150108901 fbaA gene Proteins 0.000 claims description 5
- 101150073818 gap gene Proteins 0.000 claims description 5
- 101150038284 pfkA gene Proteins 0.000 claims description 5
- 101150004013 pfkA1 gene Proteins 0.000 claims description 5
- 101150060387 pfp gene Proteins 0.000 claims description 5
- 101150053253 pgi gene Proteins 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 230000001268 conjugating effect Effects 0.000 claims description 4
- 230000002503 metabolic effect Effects 0.000 claims description 4
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 claims description 3
- 101710090836 Glucose/galactose transporter Proteins 0.000 claims description 3
- 150000008163 sugars Chemical class 0.000 claims description 3
- 229910044991 metal oxide Inorganic materials 0.000 abstract description 5
- 150000004706 metal oxides Chemical class 0.000 abstract description 5
- 210000004027 cell Anatomy 0.000 description 70
- 239000002609 medium Substances 0.000 description 25
- 239000013598 vector Substances 0.000 description 17
- 101100175632 Alkalihalobacillus halodurans (strain ATCC BAA-125 / DSM 18197 / FERM 7344 / JCM 9153 / C-125) glcK gene Proteins 0.000 description 15
- 101100174763 Mus musculus Galk1 gene Proteins 0.000 description 15
- 101150089635 glkA gene Proteins 0.000 description 15
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 14
- 150000001720 carbohydrates Chemical class 0.000 description 13
- 235000014633 carbohydrates Nutrition 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 11
- 102000030595 Glucokinase Human genes 0.000 description 10
- 108010021582 Glucokinase Proteins 0.000 description 10
- 229930027917 kanamycin Natural products 0.000 description 10
- 229960000318 kanamycin Drugs 0.000 description 10
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 10
- 229930182823 kanamycin A Natural products 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- 108091008146 restriction endonucleases Proteins 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 239000000370 acceptor Substances 0.000 description 7
- 239000013600 plasmid vector Substances 0.000 description 7
- 229960005322 streptomycin Drugs 0.000 description 7
- 238000011534 incubation Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000009466 transformation Effects 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 210000003527 eukaryotic cell Anatomy 0.000 description 4
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 210000001236 prokaryotic cell Anatomy 0.000 description 4
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 4
- 229960001225 rifampicin Drugs 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 210000002421 cell wall Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000005611 electricity Effects 0.000 description 3
- 230000037149 energy metabolism Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 2
- 101710193897 Galactose transporter Proteins 0.000 description 2
- 101710103223 Galactose-proton symporter Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 108010002747 Pfu DNA polymerase Proteins 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 241001223867 Shewanella oneidensis Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 241000588902 Zymomonas mobilis Species 0.000 description 2
- CUJRVFIICFDLGR-UHFFFAOYSA-N acetylacetonate Chemical compound CC(=O)[CH-]C(C)=O CUJRVFIICFDLGR-UHFFFAOYSA-N 0.000 description 2
- 230000004099 anaerobic respiration Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- UMRUNOIJZLCTGG-UHFFFAOYSA-N calcium;manganese Chemical compound [Ca+2].[Mn].[Mn].[Mn].[Mn] UMRUNOIJZLCTGG-UHFFFAOYSA-N 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
- -1 glucose and fructose Chemical compound 0.000 description 2
- 230000004190 glucose uptake Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 239000007769 metal material Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000011426 transformation method Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000193388 Bacillus thuringiensis Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical compound C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 241001522878 Escherichia coli B Species 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- 241001302584 Escherichia coli str. K-12 substr. W3110 Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 1
- 101710147236 Glucose facilitated diffusion protein Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- XJLXINKUBYWONI-NNYOXOHSSA-N NADP zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 102100034314 Parkin coregulated gene protein Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102100021436 UDP-glucose 4-epimerase Human genes 0.000 description 1
- 108010075202 UDP-glucose 4-epimerase Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000588901 Zymomonas Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 229940097012 bacillus thuringiensis Drugs 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 229960003669 carbenicillin Drugs 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 101150100089 gluP gene Proteins 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 101150079601 recA gene Proteins 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- ZLSOEGVSXYPCHL-UHFFFAOYSA-N sulfuric acid;tetrahydrate Chemical compound O.O.O.O.OS(O)(=O)=O ZLSOEGVSXYPCHL-UHFFFAOYSA-N 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
- Y02E60/00—Enabling technologies; Technologies with a potential or indirect contribution to GHG emissions mitigation
- Y02E60/30—Hydrogen technology
- Y02E60/50—Fuel cells
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P70/00—Climate change mitigation technologies in the production process for final industrial or consumer products
- Y02P70/50—Manufacturing or production processes characterised by the final manufactured product
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
도 2는 본 발명의 바람직한 일 실시예에 따른 재조합 플라스미드의 전기영동사진이다.
Claims (18)
- 6탄당을 대사할 수 없는 쉬와넬라 균주의 내부에, 6탄당의 흡수에 관여하는 효소를 코딩하는 외래 유전자 및 상기 6탄당의 대사에 관여하는 효소를 코딩하는 외래 유전자를 도입하여 혐기적 조건에서 6탄당을 대사하는 특성을 가지는 쉬와넬라 변이균주.
- 제1항에 있어서,
상기 쉬와넬라 균주는 쉬와넬라 오네이덴시스(Shewanella oneidensis MR-1 ATCC 700550)인 것을 특징으로 하는 쉬와넬라 변이균주. - 제1항에 있어서,
상기 6탄당은 포도당, 과당, 갈락토오스, 만니톨, 슈크로스, N-아세틸글루코사민 및 셀루비오스 중 어느 하나 이상인 것을 특징으로 하는 쉬와넬라 변이균주. - 제1항에 있어서,
상기 6탄당의 흡수에 관여하는 효소를 코딩하는 외래 유전자는 glf(ZMO0366), sugar transporter(ZMO0293), glucose-galactose transporter(SO_2213.1), glucose/galactose transporter(SO_3503) 중 어느 하나 이상이고, 6탄당의 대사에 관여하는 효소를 코딩하는 외래 유전자는 glk(ZMO0369), pgi(JW3985), pfkA(JW3887), fbaA(JW2892) 및 gapC(JW1413) 중 어느 하나 이상인 것을 특징으로 하는 쉬와넬라 변이균주. - 서열번호 1로 표시되는 전방 프라이머 및 서열번호 2로 표시되는 후방 프라이머를 포함하는 프라이머 세트.
- 서열번호 3으로 표시되는 전방 프라이머 및 서열번호 4로 표시되는 후방 프라이머를 포함하는 프라이머 세트.
- 1) 6탄당을 대사할 수 없는 쉬와넬라 균주를 준비하는 단계;
2) 상기 쉬와넬라 균주에 6탄당의 흡수에 관여하는 효소를 코딩하는 외래 유전자 및 상기 6탄당의 대사에 관여하는 효소를 코딩하는 외래 유전자를 형질전환시켜 혐기적 조건에서 6탄당을 대사하는 특성을 가지는 쉬와넬라 변이균주를 생산하는 단계를 포함하는 쉬와넬라 변이균주의 제조방법. - 제7항에 있어서,
상기 2) 단계는
a) 플라스미드에 6탄당의 흡수에 관여하는 효소를 코딩하는 외래 유전자 및 상기 6탄당의 대사에 관여하는 효소를 코딩하는 외래 유전자를 도입하여 재조합 플라스미드를 제작하는 단계;
b) 상기 재조합 플라스미드로 숙주세포를 형질전환시키는 단계; 및
c) 상기 형질전환된 숙주세포를 쉬와넬라 균주과 접합시켜 상기 재조합 플라스미드를 공여하는 단계;를 포함하는 것을 특징으로 하는 쉬와넬라 변이균주의 제조방법. - 제7항에 있어서, 상기 쉬와넬라 균주는 쉬와넬라 오네이덴시스(Shewanella oneidensis MR-1 ATCC 700550)인 것을 특징으로 하는 쉬와넬라 변이균주의 제조방법.
- 제7항에 있어서,
상기 6탄당은 포도당, 과당, 갈락토오스, 만니톨, 슈크로스, N-아세틸글루코사민 및 셀루비오스 중 어느 하나 이상인 것을 특징으로 하는 쉬와넬라 변이균주의 제조방법. - 제7항에 있어서,
상기 6탄당의 흡수에 관여하는 효소를 코딩하는 외래 유전자는 glf(ZMO0366), sugar transporter(ZMO0293), glucose-galactose transporter(SO_2213.1), glucose/galactose transporter(SO_3503) 중 어느 하나 이상이고, 6탄당의 대사에 관여하는 효소를 코딩하는 외래 유전자는 glk(ZMO0369), pgi(JW3985), pfkA(JW3887), fbaA(JW2892) 및 gapC(JW1413) 중 어느 하나 이상인 것을 특징으로 하는 쉬와넬라 변이균주의 제조방법. - 제8항에 있어서,
상기 숙주세포는 대장균인 것을 특징으로 하는 쉬와넬라 변이균주의 제조방법. - 제8항에 있어서, 상기 a) 단계는;
상기 제5항의 프라이머 세트를 이용하여 6탄당의 흡수에 관여하는 효소를 코딩하는 외래 유전자인 glf를 증폭하고, 제6항의 프라이머 세트를 이용하여 6탄당의 대사에 관여하는 효소를 코딩하는 외래 유전자인 glk를 증폭하는 단계를 포함하는 쉬와넬라 변이균주의 제조방법. - 제1항 내지 제4항 중 어느 한 항의 쉬와넬라 변이균주에 6탄당을 제공하여, 상기 6탄당의 대사과정에서 발생하는 전자를 외부 금속이온에 전달하여 상기 외부 금속이온을 환원시키는 방법.
- 제14항에 있어서, 상기 6탄당은 포도당, 과당, 갈락토오스, 만니톨, 슈크로스, N-아세틸글루코사민 및 셀루비오스 중 어느 하나 이상인 것을 특징으로 하는 방법.
- 제14항에 있어서, 상기 금속이온은 Mn(VI), Fe(III), Cr(VI) 및 U(VI) 중 어느 하나 이상인 것을 특징으로 하는 방법.
- 제1항 내지 제4항 중 어느 한 항의 쉬와넬라 변이균주를 포함하는 미생물 연료전지.
- 제17항에 있어서, 상기 쉬와넬라 변이균주가 대사할 수 있는 6탄당을 더 포함하는 것을 특징으로 하는 미생물 연료전지.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020100048104A KR101235170B1 (ko) | 2010-05-24 | 2010-05-24 | 쉬와넬라 변이균주, 제조방법 및 그 용도 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020100048104A KR101235170B1 (ko) | 2010-05-24 | 2010-05-24 | 쉬와넬라 변이균주, 제조방법 및 그 용도 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20110128582A true KR20110128582A (ko) | 2011-11-30 |
KR101235170B1 KR101235170B1 (ko) | 2013-02-21 |
Family
ID=45396744
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020100048104A Expired - Fee Related KR101235170B1 (ko) | 2010-05-24 | 2010-05-24 | 쉬와넬라 변이균주, 제조방법 및 그 용도 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101235170B1 (ko) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110791521A (zh) * | 2019-09-29 | 2020-02-14 | 天津大学前沿技术研究院 | 一种产电重组希瓦氏菌株及构建方法及用途 |
KR20200114885A (ko) * | 2019-03-29 | 2020-10-07 | 고려대학교 산학협력단 | 쉬와넬라 속에 대한 세포 표면 발현 벡터 및 이의 용도 |
CN114540396A (zh) * | 2022-02-24 | 2022-05-27 | 天津大学 | 希瓦氏菌株中葡萄糖代谢通路的构建方法 |
CN116004690A (zh) * | 2022-09-09 | 2023-04-25 | 天津大学 | 一种工程改造希瓦氏菌囊泡提高胞外电子传递的方法 |
-
2010
- 2010-05-24 KR KR1020100048104A patent/KR101235170B1/ko not_active Expired - Fee Related
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200114885A (ko) * | 2019-03-29 | 2020-10-07 | 고려대학교 산학협력단 | 쉬와넬라 속에 대한 세포 표면 발현 벡터 및 이의 용도 |
CN110791521A (zh) * | 2019-09-29 | 2020-02-14 | 天津大学前沿技术研究院 | 一种产电重组希瓦氏菌株及构建方法及用途 |
CN114540396A (zh) * | 2022-02-24 | 2022-05-27 | 天津大学 | 希瓦氏菌株中葡萄糖代谢通路的构建方法 |
CN116004690A (zh) * | 2022-09-09 | 2023-04-25 | 天津大学 | 一种工程改造希瓦氏菌囊泡提高胞外电子传递的方法 |
Also Published As
Publication number | Publication date |
---|---|
KR101235170B1 (ko) | 2013-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2023093683A (ja) | フコシル化オリゴ糖の製造のための改良された方法 | |
JP2022105118A (ja) | 取り込み/排出を改変した微生物宿主におけるヒトミルクオリゴ糖の生産 | |
CN113186142B (zh) | 一种高效生产2′-岩藻糖基乳糖的大肠杆菌工程菌株 | |
ES2941700T3 (es) | Microorganismo mutante recombinante que tiene capacidad de producción de ácido malónico y método para producir ácido malónico usando el mismo | |
CN107435049A (zh) | 一种生产红景天苷的重组大肠杆菌及构建方法及应用 | |
CN114480240A (zh) | 一种产岩藻糖基乳糖的基因工程菌及生产方法 | |
Cheng et al. | Biosynthesis of chondroitin in engineered Corynebacterium glutamicum | |
CN114262702B (zh) | 麦角硫因合成基因在谷氨酸棒杆菌中重建麦角硫因代谢途径中的应用及其方法 | |
US11673921B2 (en) | Cell-free protein synthesis platform derived from cellular extracts of Vibrio natriegens | |
WO2018188617A1 (zh) | 产3-羟基丙酸的重组菌及其制备方法与应用 | |
KR101235170B1 (ko) | 쉬와넬라 변이균주, 제조방법 및 그 용도 | |
KR20210144816A (ko) | 키메라 플라스미드 라이브러리의 구축 방법 | |
US20190169664A1 (en) | Microbial platform for production of glycosylated compounds | |
CN110734479A (zh) | 一种大肠杆菌环腺苷酸受体蛋白突变体、基因工程菌及应用 | |
JP2023520238A (ja) | 組換え微生物及び方法 | |
CN117964724A (zh) | 运输蛋白新型变体及利用其的l-芳香族氨基酸的生产方法 | |
CN106032525A (zh) | 一种合成白藜芦醇的基因工程菌及其构建方法 | |
KR20200045439A (ko) | 재조합 슈도모나스 푸티다 균주 및 이를 이용한 메발론산 생산 방법 | |
WO2021036901A1 (zh) | 支链α-酮酸脱氢酶复合体在制备丙二酸单酰辅酶A中的应用 | |
CN117904020A (zh) | 大肠杆菌乙酰化突变菌株的构建及其生产3-羟基丙酸的应用 | |
KR102336516B1 (ko) | 변이형 2-데옥시-실로-이노소스 합성효소 | |
WO2024130898A1 (zh) | 一种产2'-岩藻糖基乳糖的工程菌株及构建方法和应用 | |
US11203760B2 (en) | Gene therapy DNA vector GDTT1.8NAS12 and the method for obtaining thereof | |
JP5882415B2 (ja) | フルクトースが付加された糖質の製造方法 | |
CN116004489A (zh) | 一种生产nmn的重组大肠杆菌及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20100524 |
|
PA0201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20111031 Patent event code: PE09021S01D |
|
PG1501 | Laying open of application | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20120511 Patent event code: PE09021S01D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20130123 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20130214 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20130215 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
FPAY | Annual fee payment |
Payment date: 20151217 Year of fee payment: 4 |
|
PR1001 | Payment of annual fee |
Payment date: 20151217 Start annual number: 4 End annual number: 4 |
|
FPAY | Annual fee payment |
Payment date: 20161219 Year of fee payment: 5 |
|
PR1001 | Payment of annual fee |
Payment date: 20161219 Start annual number: 5 End annual number: 5 |
|
LAPS | Lapse due to unpaid annual fee | ||
PC1903 | Unpaid annual fee |
Termination category: Default of registration fee Termination date: 20181125 |